by Natalie J. Beveridge, PhD, Principal Consultant, Your Genes Your Health
Peptides have moved well beyond their traditional place in specialized research, attracting growing scientific, commercial and regulatory interest. The US Food and Drug Administration (FDA) has been reviewing an increasing number of peptide bulk drug substances, prompting questions about what these developments mean for research laboratories working within this space.
Much of the recent FDA activity concerns human drug compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). These provisions govern specific pathways for compounding human drugs, not laboratory research.1,2
The FDA’s assessments of peptide bulk drug substances have repeatedly examined chemical identity, physicochemical characterization and the strength of the supporting evidence. These considerations are equally relevant to laboratory procurement, where a catalog name and headline purity figure may provide little information about the precise chemical form, impurity profile or the analytical methods used to establish peptide quality.
For procurement teams, the recent regulatory reviews reinforce the importance of examining the evidence behind supplier specifications, particularly whether analytical results are traceable to the batch supplied and provide sufficient characterization for the intended research.
What has changed in the 503A and 503B reviews?
Sections 503A and 503B of the FD&C Act establish distinct pathways for human drug compounding. Section 503A principally covers compounding by licensed pharmacists and physicians for individual patients, while section 503B applies to FDA-registered outsourcing facilities, which may prepare certain compounded drugs without patient-specific prescriptions.
The pathways also differ in their requirements for bulk drug substances. Under 503A, a substance generally must comply with an applicable USP/NF monograph, be a component of an FDA-approved drug where no applicable monograph exists or appear on the 503A Bulks List. Under 503B, a bulk substance may generally be used if it appears on the 503B Bulks List or if the resulting compounded drug appears on the FDA’s drug-shortage list at a relevant point in time.1,2
Since 2023, FDA reviews of nominated bulk drug substances have included many peptides familiar to laboratories as research reagents. In January 2025, the agency revised its interim enforcement policies while development of the two Bulks Lists continues. The FDA no longer intends to place substances nominated on or after 7 January 2025 into Categories 1, 2 or 3, although substances already in those categories may remain subject to the earlier interim framework.1,2
These developments also require careful interpretation of regulatory terminology. Nomination indicates that a substance has been put forward for consideration, while a recommendation from the Pharmacy Compounding Advisory Committee (PCAC) forms part of the FDA’s evaluation rather than constituting a final decision. Inclusion on, or exclusion from, a Bulks List has a more specific regulatory consequence: it determines eligibility under the relevant compounding pathway. It does not, on its own, govern laboratory research.
Peptides are being evaluated individually
At the October and December 2024 meetings, the PCAC considered ipamorelin, kisspeptin-10, CJC-1295- related substances, AOD-9604 and thymosin alpha-1.3,4In July 2026, it reviewed seven additional peptide groups: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax and epitalon.5 Although these molecules are often grouped together as research peptides, they differ considerably in structure, biological activity and proposed applications. Their assessments therefore involve different bodies of evidence, even where similar analytical questions arise.
BPC-157 and the significance of chemical form
The FDA evaluated BPC-157 free base and BPC-157 acetate as separate bulk drug substances.6Its assessment considered the limited clinical evidence supporting the nominated uses, together with concerns about chemical characterization, peptide-related impurities and the potential to trigger an immune response. The distinction between these chemical forms also has implications for laboratory research. Peptides with identical amino acid sequences may differ in their counterions, impurity profiles and physicochemical properties, potentially affecting solubility, stability or experimental performance.
These differences can complicate the interpretation and reproducibility of published findings. Where a study identifies a peptide only by its common name, without specifying its chemical form or providing supporting analytical data, it may be difficult to establish whether a subsequently purchased reagent is comparable to the original material. Laboratories should therefore specify the required chemical form and confirm that the certificate of analysis (CoA) and supporting analytical documentation correspond to the material and batch supplied.
TB-500 and the importance of molecular identity
TB-500 illustrates the difficulties that can arise when a commonly used name does not adequately define the substance being studied. The substance considered by the FDA is an N-terminal acetylated fragment corresponding to amino acid residues 17–23 of thymosin beta-4.5 This seven-residue peptide is chemically distinct from full-length thymosin beta-4, which contains 43 amino acid residues. However, the terminology used in commercial catalogs and other sources has not always distinguished these molecules consistently.
For laboratories attempting to reproduce published findings or compare results across studies, this ambiguity has practical consequences. The amino acid sequence, molecular mass and relevant chemical modifications provide a more reliable basis for identifying a peptide than its common name alone. These details should be confirmed against the supplier’s specifications and analytical documentation before the material is incorporated into an experimental protocol.
Thymosin alpha-1 and the relevance of supporting evidence
Thymosin alpha-1 presents a different challenge in interpreting regulatory assessments. Despite a substantial body of published clinical research, the PCAC recommended against including its free-base and acetate forms on the 503A Bulks List in December 2024.4 The assessment illustrates the importance of considering the available evidence in relation to the specific uses under review. Clinical studies involving different indications, formulations, dosing regimens or routes of administration may contribute to the overall understanding of a peptide without necessarily establishing its safety or effectiveness for a particular proposed use.
A similar approach is warranted when evaluating scientific literature to inform laboratory research. The relevance of published findings depends on the material investigated, the experimental model and the conditions under which the results were obtained. Establishing these details is particularly important when selecting reagents for studies intended to reproduce or extend earlier work.
Research use remains a separate context
While a decision under sections 503A or 503B concerns eligibility for compounding, research-use-only (RUO) labeling also has a defined context. The FDA considers intended use from the circumstances surrounding a product’s marketing and distribution, rather than relying solely on statements appearing on its label.7
For laboratories, suppliers with clearly stated research-use policies and accessible technical documentation provide a sound starting point when qualifying potential suppliers.
Evaluating research peptide suppliers
The suitability of a research peptide depends on its intended application and the analytical evidence supporting its identity, purity and composition. For laboratories, supplier qualification should extend beyond catalog specifications to the documentation accompanying each batch.
Certificates of analysis and traceability
A CoA should identify the peptide, its chemical form, batch number, analytical methods, specifications and actual results. When evaluating research peptide suppliers, procurement teams should look for batch-specific CoAs, independent analytical testing and, where available, supporting chromatograms and mass spectra. These records should allow the material supplied to be traced to its analytical results, particularly when comparing suppliers or investigating experimental variability.
What does 99% HPLC purity mean?
High-performance liquid chromatography (HPLC) is widely used to assess peptide purity, but a reported value of 99% generally represents the proportion of integrated chromatographic peak area attributed to the principal component. It does not necessarily mean that 99% of the material by weight is the target peptide.
Water, counterions and residual solvents may contribute to the supplied mass without being reflected in the chromatographic result, while closely related impurities may not be fully resolved. For quantitative experiments, calculating concentrations from nominal peptide mass without accounting for actual peptide content can introduce uncertainty.
Confirming molecular identity
Mass spectrometry (MS) provides complementary evidence by determining whether the observed molecular mass is consistent with the expected peptide. Coupled with chromatography, LC-MS may also reveal certain deletion, oxidation and degradation products. However, neither HPLC nor MS alone provides a complete assessment of material quality. Peptide content, counterion composition, residual solvents and stability may require additional testing.
Matching specifications to the experiment
Since there is no universal FDA-defined research-grade standard equivalent to pharmaceutical good manufacturing practice (GMP), analytical requirements should reflect the intended application. Accurate peptide content may be essential for quantitative assays, while endotoxin contamination can influence cell-based experiments. Stability, chemical form and impurity profiles may also affect experimental outcomes.
Procurement teams should identify the material attributes relevant to their research and confirm that the supplier’s batch-specific documentation adequately characterizes them. Maintaining the connection between the supplied vial, its CoA and the underlying analytical results supports reproducibility and the investigation of unexpected findings.
What lies ahead?
The FDA has identified five additional peptides for consideration at the next PCAC meeting expected around the end of February 2027: LL-37, GHK-Cu, dihexa acetate, melanotan II and PEG-MGF.8 These reviews will continue the agency’s substance-specific evaluation of peptides nominated for human compounding, although their outcomes and broader commercial implications remain uncertain.
For research laboratories, the growing regulatory attention reinforces the value of established scientific quality standards. As interest in research peptides continues to expand, greater transparency around chemical identity, analytical testing and batch quality will help laboratories evaluate available materials with greater confidence. This will enable your procurement team to make informed decisions and, importantly, will provide a stronger foundation for reliable, reproducible research.